When should anticoagulant therapy be restarted in patients who have experienced an intracerebral hemorrhage?

When to Restart Anticoagulation After ICH

For most patients with ICH who have strong indications for anticoagulation (such as atrial fibrillation or mechanical heart valves), anticoagulation should be restarted at 4-6 weeks after the hemorrhage, with earlier resumption (7-10 days) considered only in very high thrombotic risk patients, and avoidance of resumption altogether in patients with lobar ICH due to suspected cerebral amyloid angiopathy.

Immediate Management (First 1-2 Weeks)

All anticoagulants and antiplatelet agents must be discontinued immediately upon ICH diagnosis and held for at least 1-2 weeks 1. The anticoagulant effect should be reversed urgently with appropriate agents:

• Warfarin: Use prothrombin complex concentrate (PCC) plus vitamin K 2
• Heparin: Use protamine sulfate 1
• DOACs: Consult hematology for reversal agents 2

Risk Stratification Before Resumption

The decision to restart depends on balancing two competing risks:

High Risk for Recurrent ICH (Consider NOT restarting or delaying >4 weeks):

• Lobar location of original ICH (suggests cerebral amyloid angiopathy, especially in elderly) 3
• Multiple microbleeds on gradient echo MRI 3
• Elderly patients with lobar ICH 1
• Apolipoprotein E ε2 or ε4 alleles 3

High Risk for Thromboembolism (Consider earlier resumption at 7-10 days):

• Mechanical heart valves (especially mitral position) 1, 4, 5
• Atrial fibrillation with prior stroke 1
• Recent venous thromboembolism
• Hypercoagulable states 6

Timing Algorithm by Clinical Scenario

Standard Risk Patients (Non-lobar ICH, Atrial Fibrillation Without Prior Stroke):

• Optimal timing: 4-6 weeks after ICH 3, 7, 8
• This window minimizes the composite risk of both recurrent hemorrhage and thromboembolism 3, 7
• Antiplatelet monotherapy can be restarted "in the days after ICH" if indicated, though optimal timing remains uncertain 3

Very High Thrombotic Risk (Mechanical Heart Valves):

• May restart at 7-10 days after ICH onset 1
• Meta-analysis shows no increased hazard when resuming within 7 days versus 7-30 days in mechanical valve patients 4
• Mean time to resumption in practice is approximately 12-13 days 4, 5
• Risk of recurrent ICH decreases approximately 50% by day 11 post-ICH 5
• Never withhold >30 days in mechanical valve patients—associated with significantly elevated ischemic stroke risk (HR 15.9) 4

High Risk for Recurrent ICH (Lobar ICH, Suspected Amyloid Angiopathy):

• Avoid warfarin resumption after lobar ICH 3
• Consider antiplatelet monotherapy instead for lower thrombotic risk conditions 1
• DOACs (dabigatran, rivaroxaban, apixaban) may be safer alternatives, though evidence is uncertain (Class IIb) 3
• Left atrial appendage closure may be considered as alternative to anticoagulation 9

Non-lobar (Deep) ICH:

• Anticoagulation resumption is reasonable at 4 weeks, particularly with strong indications 3
• Decision model suggests withholding improves outcomes by only 0.3 quality-adjusted life-years (versus 1.9 for lobar ICH) 3

Special Considerations

Hemorrhagic transformation of ischemic stroke (not primary ICH):

• May continue anticoagulation if asymptomatic and not progressing 1, 6
• Each case requires individual assessment based on size and symptoms 6

Subarachnoid hemorrhage:

• Do not resume until ruptured aneurysm is definitively secured 6

Choice of anticoagulant upon resumption:

• Warfarin: Maintain INR at lower end of therapeutic range with rigorous monitoring 6
• DOACs: May have lower ICH risk than warfarin in atrial fibrillation, but post-ICH data limited 3
• IV heparin may be safer than oral anticoagulation for early resumption 6

Common Pitfalls

1. Resuming too early (<7 days) in standard-risk patients increases recurrent ICH risk
2. Delaying >4-6 weeks in mechanical valve patients dramatically increases thromboembolism and mortality risk 4
3. Restarting warfarin in elderly patients with lobar ICH—high recurrence risk from probable amyloid angiopathy 1, 3
4. Failing to obtain gradient echo MRI to assess for microbleeds before resumption decision 3
5. Not consulting stroke neurology, cardiology, or hematology for complex cases 2

The evidence consistently shows that in appropriately selected patients, anticoagulation resumption reduces all-cause mortality and thromboembolism without significantly increasing recurrent ICH risk 7, 8, 9. The key is matching timing to individual risk profile.